[go: up one dir, main page]

CL2018001725A1 - Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal - Google Patents

Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal

Info

Publication number
CL2018001725A1
CL2018001725A1 CL2018001725A CL2018001725A CL2018001725A1 CL 2018001725 A1 CL2018001725 A1 CL 2018001725A1 CL 2018001725 A CL2018001725 A CL 2018001725A CL 2018001725 A CL2018001725 A CL 2018001725A CL 2018001725 A1 CL2018001725 A1 CL 2018001725A1
Authority
CL
Chile
Prior art keywords
cocristal
production
medication containing
medication
acriloilpirrolidin
Prior art date
Application number
CL2018001725A
Other languages
English (en)
Inventor
Koya Kimoto
Mitsuo Yamamoto
Masato Kitayama
Yasuhiro Sawai
Miyuki Hohokabe
Kentaro Iwata
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2018001725A1 publication Critical patent/CL2018001725A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • C07C59/50—Mandelic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COCRISTAL DE (S)-3-(1-((1-ACRILOILPIRROLIDIN-3- IL)OXI)ISOQUINOLIN-3-IL)-1H-1,2,4-TRIAZOL-5(4H)-ONA Y UN ÁCIDO ORGÁNICO CAPAZ DE FORMAR UN COCRISTAL CON EL COMPUESTO.
CL2018001725A 2015-12-24 2018-06-22 Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal CL2018001725A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015252658 2015-12-24

Publications (1)

Publication Number Publication Date
CL2018001725A1 true CL2018001725A1 (es) 2018-10-19

Family

ID=57910088

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001725A CL2018001725A1 (es) 2015-12-24 2018-06-22 Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal

Country Status (25)

Country Link
US (1) US10836745B2 (es)
EP (1) EP3394045B1 (es)
JP (1) JP6876704B2 (es)
KR (1) KR102687603B1 (es)
CN (1) CN108473467B (es)
AR (1) AR107132A1 (es)
AU (1) AU2016375899B2 (es)
CA (1) CA3009610C (es)
CL (1) CL2018001725A1 (es)
CO (1) CO2018006473A2 (es)
DK (1) DK3394045T3 (es)
EA (1) EA039213B1 (es)
EC (1) ECSP18055921A (es)
ES (1) ES2877089T3 (es)
HK (1) HK1256362A1 (es)
IL (1) IL260195A (es)
MX (1) MX380656B (es)
PH (1) PH12018501356A1 (es)
PL (1) PL3394045T3 (es)
SG (1) SG11201805331QA (es)
TN (1) TN2018000221A1 (es)
TW (1) TWI722080B (es)
UY (1) UY37046A (es)
WO (1) WO2017111179A1 (es)
ZA (1) ZA201804393B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078200C (en) * 2017-10-06 2023-09-19 Cargill, Incorporated Steviol glycoside solubility enhancers
CN111698910B (zh) 2017-10-06 2024-05-14 嘉吉公司 稳定化的甜菊醇糖苷组合物及其用途
EP3952667A1 (en) 2019-04-06 2022-02-16 Cargill, Incorporated Sensory modifiers
CN110818692B (zh) * 2019-11-08 2023-03-24 中国海洋大学 一种替加氟与丁香酸的共晶及其制备方法
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
CN117383998A (zh) * 2023-09-28 2024-01-12 天津理工大学 一种共晶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
DE69822859T2 (de) 1997-10-07 2005-01-27 Schering Corp. Krytallinischer fungizider polymorph
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CN101541618A (zh) 2007-02-28 2009-09-23 日本精工株式会社 倾斜式转向装置
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
RU2012126029A (ru) 2009-12-03 2014-01-10 Астразенека Аб Сокристаллы триазоло[4,5 d]пиримидинового ингибитора агрегации тромбоцитов
PH12014500122A1 (en) 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج

Also Published As

Publication number Publication date
CA3009610A1 (en) 2017-06-29
AR107132A1 (es) 2018-03-21
CN108473467B (zh) 2021-08-13
MX380656B (es) 2025-03-12
KR102687603B1 (ko) 2024-07-24
AU2016375899B2 (en) 2021-05-13
CO2018006473A2 (es) 2018-07-10
JP2019504025A (ja) 2019-02-14
US20170183326A1 (en) 2017-06-29
SG11201805331QA (en) 2018-07-30
EP3394045A1 (en) 2018-10-31
US10836745B2 (en) 2020-11-17
WO2017111179A1 (en) 2017-06-29
PH12018501356A1 (en) 2019-02-18
JP6876704B2 (ja) 2021-05-26
TN2018000221A1 (en) 2019-10-04
EA039213B1 (ru) 2021-12-17
UY37046A (es) 2017-07-31
ES2877089T3 (es) 2021-11-16
AU2016375899A1 (en) 2018-07-19
CA3009610C (en) 2024-02-13
HK1256362A1 (zh) 2019-09-20
BR112018012915A2 (pt) 2018-12-11
ECSP18055921A (es) 2018-10-31
CN108473467A (zh) 2018-08-31
EP3394045B1 (en) 2021-05-19
DK3394045T3 (da) 2021-08-16
MX2018007721A (es) 2018-08-15
KR20180095933A (ko) 2018-08-28
PL3394045T3 (pl) 2021-09-27
ZA201804393B (en) 2019-09-25
IL260195A (en) 2018-07-31
TW201730181A (zh) 2017-09-01
TWI722080B (zh) 2021-03-21
EA201891467A1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
CL2018001725A1 (es) Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
BR112018010118A2 (pt) inibidores de cxcr2
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
CL2018003267A1 (es) Cápsulas que comprenden bencilpropargiléteres para usar como inhibidores de la nitrificación.
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
WO2015155303A3 (en) Medical use of artemisinin compounds and gephyrin agonists
CR20150423A (es) Proceso de fabricación de vortioxetina
CR20220233A (es) Sulfonamidas sustituidas para el control de plagas animales
NZ773183A (en) Mini-gde for the treatment of glycogen storage disease iii
MX2020013849A (es) Nuevos compuestos de sulfonilaminobenzamida como antihelminticos.
BR112016028801A2 (pt) inibidores de moléculas pequenas de lfa-1
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
CL2018002347A1 (es) Nuevos derivados pirrolidina
EA201791620A1 (ru) Способ разложения материала биомассы, содержащего лигноцеллюлозу
TH176870A (th) สารประกอบพิโคลิแนมีดที่มีฤทธิ์ฆ่ารา
TH1501004770A (th) สารกระตุ้นพาธเวย์ที่ให้สัญญาณ (แกมมา)-ไดคีโตนที่เป็น wnt/(เบต้า)-คาเทนิน
TH168459A (th) สารประกอบใหม่สำหรับการรักษาภาวะน้ำตาลในเลือดต่ำอย่างรุนเเรง